Second Sight Medical Products, Inc. (NASDAQ:EYES) Director Gregg Williams bought 17,020 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average cost of $1.18 per share, with a total value of $20,083.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gregg Williams also recently made the following trade(s):

  • On Friday, November 17th, Gregg Williams bought 5,420 shares of Second Sight Medical Products stock. The shares were bought at an average cost of $1.17 per share, with a total value of $6,341.40.

Second Sight Medical Products, Inc. (NASDAQ EYES) traded up $0.04 on Friday, reaching $1.22. The company had a trading volume of 446,024 shares, compared to its average volume of 388,578. Second Sight Medical Products, Inc. has a 1 year low of $0.90 and a 1 year high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last released its earnings results on Thursday, November 2nd. The medical device company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative return on equity of 184.87% and a negative net margin of 565.12%. The firm had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $1.54 million. analysts anticipate that Second Sight Medical Products, Inc. will post -0.55 earnings per share for the current fiscal year.

Several research analysts recently commented on the company. HC Wainwright set a $5.00 target price on Second Sight Medical Products and gave the stock a “buy” rating in a research note on Tuesday, August 29th. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.

A hedge fund recently raised its stake in Second Sight Medical Products stock. Vanguard Group Inc. grew its holdings in shares of Second Sight Medical Products, Inc. (NASDAQ:EYES) by 0.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 843,462 shares of the medical device company’s stock after buying an additional 5,973 shares during the period. Vanguard Group Inc. owned 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.82% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/insider-buying-second-sight-medical-products-inc-eyes-director-buys-20083-60-in-stock/1726154.html.

About Second Sight Medical Products

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.